These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial. Serrano PE; Gu CS; Moulton CA; Husien M; Jalink D; Martel G; Tsang ME; Hallet J; McAlister V; Gallinger S; Levine M J Surg Oncol; 2020 May; 121(6):1001-1006. PubMed ID: 32034769 [TBL] [Abstract][Full Text] [Related]
23. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767 [TBL] [Abstract][Full Text] [Related]
24. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Staib L; Schirrmeister H; Reske SN; Beger HG Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130 [TBL] [Abstract][Full Text] [Related]
25. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. Metser U; You J; McSweeney S; Freeman M; Hendler A AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157 [TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Desai DC; Zervos EE; Arnold MW; Burak WE; Mantil J; Martin EW Ann Surg Oncol; 2003; 10(1):59-64. PubMed ID: 12513962 [TBL] [Abstract][Full Text] [Related]
27. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Wiering B; Ruers TJ; Oyen WJ Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664 [TBL] [Abstract][Full Text] [Related]
28. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241 [TBL] [Abstract][Full Text] [Related]
30. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Watson AJ; Lolohea S; Robertson GM; Frizelle FA Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340 [TBL] [Abstract][Full Text] [Related]
31. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. Laurens ST; Oyen WJ PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671 [TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Patel S; McCall M; Ohinmaa A; Bigam D; Dryden DM Ann Surg; 2011 Apr; 253(4):666-71. PubMed ID: 21475005 [TBL] [Abstract][Full Text] [Related]
34. Positron emission tomography and colorectal cancer. Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864 [TBL] [Abstract][Full Text] [Related]
35. [Positron emission tomography/computed tomography in follow-up programmes for patients with colorectal cancer]. Hansen AF; Jensen MR; Nordholm-Carstensen A Ugeskr Laeger; 2016 Sep; 178(37):. PubMed ID: 27649583 [TBL] [Abstract][Full Text] [Related]
36. Management of recurrent colorectal cancer with positron emission tomography. Haji A Br J Hosp Med (Lond); 2007 Nov; 68(11):580-3. PubMed ID: 18087843 [TBL] [Abstract][Full Text] [Related]